menu
    • menu
    [{"orgOrder":0,"company":"Union Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Orismilast","moa":"PDE4","graph1":"Immunology","graph2":"Phase II","graph3":"Union Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Union Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Union Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Union Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Niclosamide","moa":"DNA","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Union Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Union Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Union Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Union Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Niclosamide","moa":"DNA","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Union Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Union Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Union Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Union Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Niclosamide","moa":"DNA","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Union Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Union Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Union Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Union Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Niclosamide","moa":"DNA","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Union Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Union Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Union Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Union Therapeutics","sponsor":"Institut Pasteur Korea","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Niclosamide","moa":"DNA","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Union Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Union Therapeutics \/ Institut Pasteur Korea","highestDevelopmentStatusID":"8","companyTruncated":"Union Therapeutics \/ Institut Pasteur Korea"},{"orgOrder":0,"company":"Union Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Orismilast","moa":"PDE4","graph1":"Dermatology","graph2":"Phase II","graph3":"Union Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Union Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Union Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Union Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Orismilast","moa":"PDE4","graph1":"Dermatology","graph2":"Phase II","graph3":"Union Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Union Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Union Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Union Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Orismilast","moa":"PDE4","graph1":"Dermatology","graph2":"Phase II","graph3":"Union Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Union Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Union Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Union Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Orismilast","moa":"PDE4","graph1":"Dermatology","graph2":"Phase II","graph3":"Union Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Union Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Union Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Union Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Orismilast","moa":"PDE4","graph1":"Dermatology","graph2":"Phase II","graph3":"Union Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Union Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Union Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Union Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Orismilast","moa":"PDE4","graph1":"Dermatology","graph2":"Phase II","graph3":"Union Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Union Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Union Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Union Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Orismilast","moa":"PDE4","graph1":"Dermatology","graph2":"Phase II","graph3":"Union Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Union Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Union Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Union Therapeutics","sponsor":"Innovent Biologics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Orismilast","moa":"PDE4","graph1":"Dermatology","graph2":"Phase II","graph3":"Union Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Union Therapeutics \/ Innovent Biologics","highestDevelopmentStatusID":"8","companyTruncated":"Union Therapeutics \/ Innovent Biologics"}]

    Find Clinical Drug Pipeline Developments & Deals by Union Therapeutics

    Menu

    Union Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Union Therapeutics

                            Denmark arrow
                            IFT FIRST
                            Not Confirmed

                            Union Therapeutics

                            Denmark arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Orismilast

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            UNION Shares Phase 2a Orismilast Data in Ulcerative Colitis at 20th ECCO Congress

                            Details : UNI50001 (orismilast) is a potent PDE4B/D inhibitor, which is being investigated in adults with moderate-to-severe ulcerative colitis.

                            Product Name : UNI50001

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            February 21, 2025

                            Lead Product(s) : Orismilast

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Union Therapeutics

                            Denmark arrow
                            IFT FIRST
                            Not Confirmed

                            Union Therapeutics

                            Denmark arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Orismilast

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            UNION Reports Phase 2b Results for Orismilast in Atopic Dermatitis, Confirming Efficacy

                            Details : UNI50001 (orismilast) is a next-generation, high-potency PDE4 inhibitor targeting the PDE4B/D subtypes. Currently, it is being evaluated for the treatment of Atopic Dermatitis.

                            Product Name : UNI50001

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            September 25, 2024

                            Lead Product(s) : Orismilast

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Union Therapeutics

                            Denmark arrow
                            IFT FIRST
                            Not Confirmed

                            Union Therapeutics

                            Denmark arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Orismilast

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            UNION Completes Phase 2b Study of ADESOS, Data Presented at RAVE 2024

                            Details : UNI50001 (orismilast) is a potent PDE4B/D inhibitor, which is being investigated in adults with moderate-to-severe atopic dermatitis.

                            Product Name : UNI50001

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            April 06, 2024

                            Lead Product(s) : Orismilast

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Union Therapeutics

                            Denmark arrow
                            IFT FIRST
                            Not Confirmed

                            Union Therapeutics

                            Denmark arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Orismilast

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            UNION Therapeutics Announces Positive Topline Results from The IASOS Phase 2b Study of Oral Orismilast in Pati...

                            Details : UNI50001 (orismilast), a high-potency PDE4 inhibitor linked to inflammation. Orismilast holds the potential to become a safe and efficacious oral treatment for many immunological diseases, and is currently developing oral orismilast for the treatment of ...

                            Product Name : UNI50001

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            September 01, 2023

                            Lead Product(s) : Orismilast

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Union Therapeutics

                            Denmark arrow
                            IFT FIRST
                            Not Confirmed

                            Union Therapeutics

                            Denmark arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Orismilast

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Union Therapeutics Announces Positive Topline Results from the Osiris Investigator-Initiated Proof-of-Concept ...

                            Details : UNI50001 (orismilast) is a high-potency, oral, next-generation PDE4 inhibitor targeting the PDE4 subtypes linked to inflammation, being developed in patients with hidradenitis suppurativa and also in atopic dermatitis (AD) and psoriasis.

                            Product Name : UNI50001

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            June 21, 2023

                            Lead Product(s) : Orismilast

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Union Therapeutics

                            Denmark arrow
                            IFT FIRST
                            Not Confirmed

                            Union Therapeutics

                            Denmark arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Orismilast

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Union Therapeutics Presents New Data on Orismilast at the 31st EADV Congress Supporting Orismilast’s Potenti...

                            Details : Preclinical data demonstrated that UNI50001 (orismilast) is potent inhibitor of phosphodiesterase type-4 (PDE4), and that orismilast more selectively inhibit PDE4B and PDE4D subtypes which are considered more relevant in treatment of immunological diseas...

                            Product Name : UNI50001

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            September 09, 2022

                            Lead Product(s) : Orismilast

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Union Therapeutics

                            Denmark arrow
                            IFT FIRST
                            Not Confirmed

                            Union Therapeutics

                            Denmark arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Orismilast

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            UNION therapeutics Announces Enrollment of the First Patient in ADESOS Phase 2b Study of Orismilast MR Tablet ...

                            Details : UNION is developing orismilast, which is a potent next-generation phosphodiesterase type-4 (PDE4) inhibitor operating early in the inflammation cascade to induce a broad spectrum of downstream anti-inflammatory effects.

                            Product Name : UNI50001

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            April 08, 2022

                            Lead Product(s) : Orismilast

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Union Therapeutics

                            Denmark arrow
                            IFT FIRST
                            Not Confirmed

                            Union Therapeutics

                            Denmark arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Orismilast

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Innovent Biologics

                            Deal Size : $267.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            UNION therapeutics and Innovent Biologics Enter Into Strategic Collaboration and License Agreement for Orismil...

                            Details : Under the terms of the agreement, UNION grants Innovent an exclusive license to research, develop and commercialize orismilast in China, including participating in and recruiting Chinese patients for potential future global studies of orismilast.

                            Product Name : UNI50001

                            Product Type : Other Small Molecule

                            Upfront Cash : $20.0 million

                            September 28, 2021

                            Lead Product(s) : Orismilast

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Innovent Biologics

                            Deal Size : $267.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Union Therapeutics

                            Denmark arrow
                            IFT FIRST
                            Not Confirmed

                            Union Therapeutics

                            Denmark arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Orismilast

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            UNION Therapeutics A/S Receives FDA Approval for IND of Oral Next-Gen PDE4-Inhibitor for investigation in Plaq...

                            Details : Orismilast is a next generation oral PDE4-inhibitor with an improved therapeutic window compared to other PDE4-inhibitors. Oral orismilast (UNI50001) has demonstrated proof of concept in patients living with plaque psoriasis and indicated "best-in-class...

                            Product Name : UNI50001

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            July 01, 2021

                            Lead Product(s) : Orismilast

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Union Therapeutics

                            Denmark arrow
                            IFT FIRST
                            Not Confirmed

                            Union Therapeutics

                            Denmark arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Niclosamide

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            UNI91103, Developed By UNION therapeutics A/S, Selected as First Agent for Prophylactic Covid-19 "protect-V" S...

                            Details : UNION therapeutics A/S (UNION) has been selected by Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge to trial UNI91103 as a prophylactic treatment of COVID-19 in kidney patients, a vulnerable and high-risk patient popul...

                            Product Name : UNI911

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            February 22, 2021

                            Lead Product(s) : Niclosamide

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth